<p>Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - 获取免费报告) 的股价在周二交易中下跌了 1.9%。该公司的股价最低曾达到 3.11 美元，最后交易价为 3.14 美元。在午间交易中，约有 325,694 股易手，较平均每日交易量 400,771 股下降了 19%。该股票此前收盘价为 3.20 美元。</p>
<p>获取 <strong>Atea Pharmaceuticals</strong> 的提醒：</p>
<h2>华尔街分析师预测增长</h2>
<p>几位股票分析师最近对 AVIR 股票发表了评论。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Atea Pharmaceuticals 的 “卖出（d-）” 评级。Evercore ISI 在 11 月 28 日的报告中将 Atea Pharmaceuticals 的评级上调至 “强力买入”。一位分析师给予该股票强力买入评级，一位给予买入评级，一位给予持有评级，还有一位给予卖出评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 6.00 美元。</p>
<p><strong>查看我们关于 Atea Pharmaceuticals 的最新报告</strong></p>
<h2>Atea Pharmaceuticals 股价下跌 1.9%</h2>
<p>该公司的 50 日简单移动平均线为 3.13 美元，200 日简单移动平均线为 3.28 美元。该公司的市值为 2.4533 亿美元，市盈率为-1.77，贝塔值为 0.16。</p>
<p>Atea Pharmaceuticals (NASDAQ:AVIR - 获取免费报告) 最近在 11 月 12 日发布了其财报。该公司报告的每股收益（EPS）为-0.53 美元，低于分析师的共识预期-0.46 美元，差距为 0.07 美元。研究分析师平均预测 Atea Pharmaceuticals, Inc.在当前财年的每股收益将为-2.01 美元。</p>
<h2>对 Atea Pharmaceuticals 的对冲基金看法</h2>
<p>几家对冲基金和其他机构投资者最近对 AVIR 的持仓进行了调整。Prudential Financial Inc.在第二季度购买了价值约 36,000 美元的 Atea Pharmaceuticals 新头寸。Johnson Investment Counsel Inc.在第二季度收购了价值约 55,000 美元的 Atea Pharmaceuticals 新股份。BNP Paribas Financial Markets 在第三季度将其在 Atea Pharmaceuticals 的持股增加了 57.7%。BNP Paribas Financial Markets 目前拥有该公司 19,913 股股票，价值 58,000 美元，此前在该期间又购买了 7,286 股。SG Americas Securities LLC 在第三季度购买了价值约 59,000 美元的 Atea Pharmaceuticals 新股份。最后，Certified Advisory Corp 在第三季度收购了价值约 71,000 美元的 Atea Pharmaceuticals 新头寸。机构投资者和对冲基金持有该公司 86.67% 的股份。</p>
<h2>Atea Pharmaceuticals 公司简介</h2>
<p>(获取免费报告)</p>
<p>Atea Pharmaceuticals, Inc.是一家临床阶段的生物制药公司，专注于为病毒感染患者发现、开发和商业化抗病毒治疗。其主要产品候选药物是 AT-527，一种口服抗病毒候选药物，目前正在进行针对 COVID-19 患者的第三阶段 SUNRISE-3 临床试验。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票比 Atea Pharmaceuticals 更好</li>
<li>内部交易可能不会告诉你你想的那样</li>
<li>消费者得到了煤炭，但圣诞老人给这两家零售商带来了巨大的收益</li>
<li>什么是低市盈率，它对投资者意味着什么？</li>
<li>10 倍收益？这三只机器人股票可能在 2035 年前爆炸</li>
<li>最佳能源股票 - 现在值得购买的能源股票</li>
<li>安海斯 - 布希收购 BeatBox 以吸引年轻饮酒者</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Atea Pharmaceuticals 吗？</h2>
<p>在你考虑 Atea Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Atea Pharmaceuticals 并不在名单上。</p>
<p>虽然 Atea Pharmaceuticals 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

AVIR

<p>Atea Pharmaceuticals（纳斯达克代码：AVIR）股票下跌 1.9%，至 3.14 美元，交易量较平均水平下降 19%。分析师的评级各不相同：一项强烈买入、一项买入、一项持有和一项卖出，整体共识为适度买入，目标价格为 6.00 美元。该公司报告第三季度每股收益为（0.53 美元），未能达到预期。机构投资者持有 86.67% 的股份。Atea 正在开发 AT-527，这是一种针对 COVID-19 的抗病毒药物，目前处于第三阶段试验中</p>

<p>Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Get Free Report)'s stock price was down 1.9% during trading on Tuesday . The company traded as low as $3.11 and last traded at $3.14. Approximately 325,694 shares changed hands during mid-day trading, a decline of 19% from the average daily volume of 400,771 shares. The stock had previously closed at $3.20.</p>
<div class="lb-trans"><p>Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - 获取免费报告) 的股价在周二交易中下跌了 1.9%。该公司的股价最低曾达到 3.11 美元，最后交易价为 3.14 美元。在午间交易中，约有 325,694 股易手，较平均每日交易量 400,771 股下降了 19%。该股票此前收盘价为 3.20 美元。</p>
</div><p>Get <strong>Atea Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Atea Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several equities analysts recently commented on AVIR shares. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Atea Pharmaceuticals in a research note on Wednesday, October 8th. Evercore ISI upgraded Atea Pharmaceuticals to a &#34;strong-buy&#34; rating in a report on Friday, November 28th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $6.00.</p>
<div class="lb-trans"><p>几位股票分析师最近对 AVIR 股票发表了评论。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Atea Pharmaceuticals 的 “卖出（d-）” 评级。Evercore ISI 在 11 月 28 日的报告中将 Atea Pharmaceuticals 的评级上调至 “强力买入”。一位分析师给予该股票强力买入评级，一位给予买入评级，一位给予持有评级，还有一位给予卖出评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 6.00 美元。</p>
</div><p><strong>View Our Latest Report on Atea Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Atea Pharmaceuticals 的最新报告</strong></p>
</div><h2>Atea Pharmaceuticals Stock Down 1.9%</h2>
<div class="lb-trans"><h2>Atea Pharmaceuticals 股价下跌 1.9%</h2>
</div><p>The company has a 50 day simple moving average of $3.13 and a 200 day simple moving average of $3.28. The company has a market capitalization of $245.33 million, a price-to-earnings ratio of -1.77 and a beta of 0.16.</p>
<div class="lb-trans"><p>该公司的 50 日简单移动平均线为 3.13 美元，200 日简单移动平均线为 3.28 美元。该公司的市值为 2.4533 亿美元，市盈率为-1.77，贝塔值为 0.16。</p>
</div><p>Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) last issued its earnings results on Wednesday, November 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.07). On average, research analysts forecast that Atea Pharmaceuticals, Inc. will post -2.01 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Atea Pharmaceuticals (NASDAQ:AVIR - 获取免费报告) 最近在 11 月 12 日发布了其财报。该公司报告的每股收益（EPS）为-0.53 美元，低于分析师的共识预期-0.46 美元，差距为 0.07 美元。研究分析师平均预测 Atea Pharmaceuticals, Inc.在当前财年的每股收益将为-2.01 美元。</p>
</div><h2>Hedge Funds Weigh In On Atea Pharmaceuticals</h2>
<div class="lb-trans"><h2>对 Atea Pharmaceuticals 的对冲基金看法</h2>
</div><p>Several hedge funds and other institutional investors have recently made changes to their positions in AVIR. Prudential Financial Inc. purchased a new position in Atea Pharmaceuticals in the second quarter valued at about $36,000. Johnson Investment Counsel Inc. acquired a new stake in shares of Atea Pharmaceuticals in the second quarter valued at about $55,000. BNP Paribas Financial Markets raised its holdings in shares of Atea Pharmaceuticals by 57.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 19,913 shares of the company's stock valued at $58,000 after buying an additional 7,286 shares during the period. SG Americas Securities LLC purchased a new stake in shares of Atea Pharmaceuticals during the 3rd quarter valued at about $59,000. Finally, Certified Advisory Corp acquired a new position in Atea Pharmaceuticals during the 3rd quarter worth approximately $71,000. Institutional investors and hedge funds own 86.67% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近对 AVIR 的持仓进行了调整。Prudential Financial Inc.在第二季度购买了价值约 36,000 美元的 Atea Pharmaceuticals 新头寸。Johnson Investment Counsel Inc.在第二季度收购了价值约 55,000 美元的 Atea Pharmaceuticals 新股份。BNP Paribas Financial Markets 在第三季度将其在 Atea Pharmaceuticals 的持股增加了 57.7%。BNP Paribas Financial Markets 目前拥有该公司 19,913 股股票，价值 58,000 美元，此前在该期间又购买了 7,286 股。SG Americas Securities LLC 在第三季度购买了价值约 59,000 美元的 Atea Pharmaceuticals 新股份。最后，Certified Advisory Corp 在第三季度收购了价值约 71,000 美元的 Atea Pharmaceuticals 新头寸。机构投资者和对冲基金持有该公司 86.67% 的股份。</p>
</div><h2>Atea Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Atea Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.</p>
<div class="lb-trans"><p>Atea Pharmaceuticals, Inc.是一家临床阶段的生物制药公司，专注于为病毒感染患者发现、开发和商业化抗病毒治疗。其主要产品候选药物是 AT-527，一种口服抗病毒候选药物，目前正在进行针对 COVID-19 患者的第三阶段 SUNRISE-3 临床试验。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Atea Pharmaceuticals</li>
<li>Insider Trades May Not Tell You What You Think</li>
<li>Consumers Got Coal, But Santa Dropped Off Big Gains for These 2 Retailers</li>
<li>What is a Low P/E Ratio and What Does it Tell Investors?</li>
<li>10X Gains? These 3 Robotics Stocks Could Explode by 2035</li>
<li>Best Energy Stocks - Energy Stocks to Buy Now</li>
<li>Anheuser-Busch Buys BeatBox to Win Over Younger Drinkers</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Atea Pharmaceuticals 更好</li>
<li>内部交易可能不会告诉你你想的那样</li>
<li>消费者得到了煤炭，但圣诞老人给这两家零售商带来了巨大的收益</li>
<li>什么是低市盈率，它对投资者意味着什么？</li>
<li>10 倍收益？这三只机器人股票可能在 2035 年前爆炸</li>
<li>最佳能源股票 - 现在值得购买的能源股票</li>
<li>安海斯 - 布希收购 BeatBox 以吸引年轻饮酒者</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Atea Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Atea Pharmaceuticals 吗？</h2>
</div><p>Before you consider Atea Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Atea Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atea Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Atea Pharmaceuticals 并不在名单上。</p>
</div><p>While Atea Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Atea Pharmaceuticals 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Atea Pharmaceuticals（NASDAQ:AVIR）股价下跌 1.9% - 你是否应该卖出？